Upfront $8 Million in Gross Proceeds and potential $40 million in Gross Proceeds from Exercise of Additional Investment Rights TYLER, Texas / Jul 18, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices for enteral feeding, pain management and urological conditions, today announced it has entered into a definitive... Read More